Kamada Stock Price, News & Analysis (NASDAQ:KMDA) $4.78 +0.02 (+0.42%) (As of 11/28/2023 ET) Add Compare Share Share Today's Range$4.76▼$4.8250-Day Range$4.14▼$5.3852-Week Range$3.72▼$5.85Volume11,269 shsAverage Volume30,060 shsMarket Capitalization$214.46 millionP/E Ratio36.81Dividend YieldN/APrice Target$11.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Kamada MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside129.9% Upside$11.00 Price TargetShort InterestHealthy0.05% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment0.51Based on 3 Articles This WeekInsider TradingN/AProj. Earnings Growth107.69%From $0.13 to $0.27 Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.60 out of 5 starsMedical Sector119th out of 949 stocksPharmaceutical Preparations Industry40th out of 436 stocks 3.5 Analyst's Opinion Consensus RatingKamada has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $11.00, Kamada has a forecasted upside of 129.9% from its current price of $4.79.Amount of Analyst CoverageKamada has only been the subject of 1 research reports in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted0.05% of the float of Kamada has been sold short.Short Interest Ratio / Days to CoverKamada has a short interest ratio ("days to cover") of 0.7, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Kamada has recently increased by 20.51%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldKamada does not currently pay a dividend.Dividend GrowthKamada does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for KMDA. Previous Next 2.0 News and Social Media Coverage News SentimentKamada has a news sentiment score of 0.51. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.88 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 3 news articles for Kamada this week, compared to 1 article on an average week. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Kamada insiders have not sold or bought any company stock.Percentage Held by Insiders36.10% of the stock of Kamada is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 34.08% of the stock of Kamada is held by institutions. Previous Next 3.1 Earnings and Valuation Earnings GrowthEarnings for Kamada are expected to grow by 107.69% in the coming year, from $0.13 to $0.27 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Kamada is 36.81, which means that it is trading at a less expensive P/E ratio than the market average P/E ratio of about 117.96.Price to Earnings Ratio vs. SectorThe P/E ratio of Kamada is 36.81, which means that it is trading at a less expensive P/E ratio than the Medical sector average P/E ratio of about 111.50.Price to Book Value per Share RatioKamada has a P/B Ratio of 1.22. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About Kamada Stock (NASDAQ:KMDA)Kamada Ltd., together with its subsidiaries, provides plasma-derived protein therapeutics. It operates in two segments, Proprietary Products and Distribution. The company offers WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; VARIZIG for post exposure prophylaxis of varicella; and GLASSIA for intravenous AATD. It also provides KamRho (D) IM for prophylaxis of hemolytic disease of newborns; KamRho (D) IV for immune thermobocytopunic purpura; and snake bite antiserum to treat snake bites by the vipera palaestinae and echis coloratus. In addition, the company distributes BRAMITOB to manage chronic pulmonary infection; FOSTER to treat asthma; PROVOCHOLINE for the diagnosis of bronchial airway hyperactivity; AEROBIKA, an OPEP device; RUPAFIN for Allergic rhinitis and Urticaria; IVIG for immunodeficiency-related conditions; VARITECT for chicken pox and zoster herpes; ZUTECTRA and HEPATECT CP for hepatitis B; MEGALOTECT CP for cytomegalovirus virus; RUCONEST for angioedema attacks; heparin sodium injection for thrombo-embolic disorders and prophylaxis of deep vein thrombosis and thromboembolic events; ALBUMIN for blood plasma; Factor VIII for hemophilia type A; and Factor IX for hemophilia type B. Further, it offers IXIARO for Japanese encephalitis; VIVOTIF for Salmonella Typhi; PROCYSBI for nephropathic cystinosis; LAMZEDE for alpha-mannosidosis; and ELIGARD for prostate cancer. The company markets its products through strategic partners in the United States, as well as through distributors internationally. It has strategic partnerships with Takeda Pharmaceuticals Company Limited; PARI GmbH; and Kedrion Biopharma. Kamada Ltd. was incorporated in 1990 and is headquartered in Rehovot, Israel.Read More KMDA Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart KMDA Stock News HeadlinesNovember 25, 2023 | americanbankingnews.comKamada (NASDAQ:KMDA) Share Price Crosses Below Two Hundred Day Moving Average of $5.06November 18, 2023 | americanbankingnews.comKamada's (KMDA) Buy Rating Reiterated at HC WainwrightNovember 28, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 15, 2023 | finance.yahoo.comKMDA: $37.9 Million in 3Q23 Revenues; Closes $60 Million Private Placement with FIMI Opportunity Funds…November 14, 2023 | benzinga.comKamada Stock (NASDAQ:KMDA) Earnings Dates and Earning CallsNovember 13, 2023 | msn.comKamada beats Q3 top and bottom line estimates; reaffirms FY23 outlookNovember 13, 2023 | finance.yahoo.comKamada: Q3 Earnings SnapshotNovember 12, 2023 | markets.businessinsider.comHere's what Wall Street expects from Kamada's earnings reportNovember 28, 2023 | Autonomix (Ad)[Investor Alert] Potential Breakthrough Medical Tech Investment OpportunityAutonomix has patented technology that can detect and target nerve signals at an accuracy never seen before, a $100B opportunity. Now the team with almost $600M in exits is planning to list Autonomix on the Nasdaq. And you can invest in Autonomix ahead of their intended Nasdaq listing.* *Disclosure: This is a paid advertisement for Autonomix’s Regulation A+ Offering. Please read the offering circular at invest.autonomix.comNovember 10, 2023 | msn.comKamada Q3 2023 Earnings PreviewNovember 9, 2023 | msn.comFootball: Kamada, Doan recalled for Japan's World Cup qualifiersNovember 8, 2023 | finance.yahoo.comKamada to Announce Third Quarter and First Nine Months Ended September 30, 2023 Financial Results and Host Conference Call on November 13, 2023October 10, 2023 | finanznachrichten.deKamada Ltd.: Kamada Provides Corporate Update on its Israel OperationsOctober 10, 2023 | marketwatch.comKamada Operations Continuing in IsraelOctober 10, 2023 | finance.yahoo.comKamada Provides Corporate Update on its Israel OperationsAugust 30, 2023 | finance.yahoo.comKamada Announces Shareholder Approval and Planned Closing of $60 Million Private Placement with FIMI Opportunity FundsAugust 21, 2023 | finance.yahoo.comKMDA: 2Q23 Revenues up 59% YoY; Reiterates 2023 Revenue Guidance of $138 Million to $146 Million…August 16, 2023 | finanznachrichten.deKamada Ltd.: Kamada Reports Strong Second Quarter and First Half 2023 Financial Results; Reiterates 2023 Revenue and Profitability GuidanceAugust 16, 2023 | markets.businessinsider.comKamada Reports Strong Second Quarter and First Half 2023 Financial Results; Reiterates 2023 Revenue and Profitability GuidanceAugust 16, 2023 | sfgate.comKamada: Q2 Earnings SnapshotAugust 15, 2023 | markets.businessinsider.comKamada earnings preview: what to expectAugust 9, 2023 | finance.yahoo.comKamada to Announce Second Quarter and First Half Ended June 30, 2023 Financial Results and Host Conference Call on August 16, 2023August 5, 2023 | msn.comFootball: Kamada seals move to Lazio in Italian Serie AAugust 3, 2023 | msn.comFootball: Japan midfielder Kamada headed to Lazio: ReportsJuly 12, 2023 | msn.comSpurs: Lilywhites have long-standing Kamada interestJuly 11, 2023 | msn.comSpurs: Daichi Kamada could be Maddison's perfect partnerJune 21, 2023 | msn.comKamada: Deep Dive Following FIMI Placement, Rate BuySee More Headlines Receive KMDA Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Kamada and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/16/2023Today11/28/2023Fiscal Year End12/31/2023Next Earnings (Estimated)3/20/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KMDA CUSIPN/A CIK1567529 Webwww.kamada.com Phone(728) 940-6472Fax972-8940-6473Employees380Year FoundedN/APrice Target and Rating Average Stock Price Target$11.00 High Stock Price Target$11.00 Low Stock Price Target$11.00 Potential Upside/Downside+129.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)$0.13 Trailing P/E Ratio36.81 Forward P/E Ratio36.81 P/E GrowthN/ANet Income$-2,320,000.00 Net Margins4.07% Pretax Margin4.19% Return on Equity5.93% Return on Assets3.52% Debt Debt-to-Equity RatioN/A Current Ratio4.11 Quick Ratio2.13 Sales & Book Value Annual Sales$129.34 million Price / Sales1.66 Cash Flow$0.03 per share Price / Cash Flow183.16 Book Value$3.93 per share Price / Book1.22Miscellaneous Outstanding Shares44,820,000Free Float28,640,000Market Cap$214.46 million OptionableNot Optionable Beta0.95 10 Best Cheap Stocks to Buy NowMarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.Get This Free Report Key ExecutivesMr. Amir London (Age 54)Chief Executive Officer Comp: $619kMr. Chaime Orlev (Age 53)Chief Financial Officer Comp: $396kMr. Eran Nir (Age 50)Chief Operating Officer Comp: $371kMr. Boris Gorelik (Age 42)Vice President of Business Development & Strategic Programs Comp: $337kMr. David Tsur (Age 73)Co-Founder & Deputy Chairman of the Board Comp: $252kMr. Nir Livneh B.A. (Age 44)L.L.B., VP, General Counsel & Corporate Secretary Ms. Hanni Neheman (Age 53)Vice President of Marketing & Sales Ms. Liron Reshef (Age 52)Vice President of Human Resources Mr. Jon R. KnightVice President of US Commercial OperationsMs. Shavit BeladevVice President of Kamada PlasmaMore ExecutivesKey CompetitorsLifecore BiomedicalNASDAQ:LFCRSCYNEXISNASDAQ:SCYXRockwell MedicalNASDAQ:RMTIPetIQNASDAQ:PETQEvolusNASDAQ:EOLSView All CompetitorsInstitutional OwnershipAcadian Asset Management LLCSold 42,417 shares on 11/13/2023Ownership: 1.169%Altshuler Shaham LtdSold 33,232 shares on 11/13/2023Ownership: 0.592%Meitav Investment House Ltd.Bought 11,284 shares on 10/30/2023Ownership: 0.171%Y.D. More Investments LtdBought 14,002 shares on 10/30/2023Ownership: 0.031%View All Institutional Transactions KMDA Stock Analysis - Frequently Asked Questions Should I buy or sell Kamada stock right now? 1 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for Kamada in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" KMDA shares. View KMDA analyst ratings or view top-rated stocks. What is Kamada's stock price target for 2024? 1 Wall Street research analysts have issued twelve-month target prices for Kamada's shares. Their KMDA share price targets range from $11.00 to $11.00. On average, they predict the company's share price to reach $11.00 in the next twelve months. This suggests a possible upside of 129.9% from the stock's current price. View analysts price targets for KMDA or view top-rated stocks among Wall Street analysts. How have KMDA shares performed in 2023? Kamada's stock was trading at $4.01 at the beginning of 2023. Since then, KMDA stock has increased by 19.3% and is now trading at $4.7850. View the best growth stocks for 2023 here. Are investors shorting Kamada? Kamada saw a increase in short interest in the month of November. As of November 15th, there was short interest totaling 14,100 shares, an increase of 20.5% from the October 31st total of 11,700 shares. Based on an average daily trading volume, of 20,300 shares, the days-to-cover ratio is presently 0.7 days. Currently, 0.1% of the shares of the stock are short sold. View Kamada's Short Interest. When is Kamada's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 20th 2024. View our KMDA earnings forecast. How were Kamada's earnings last quarter? Kamada Ltd. (NASDAQ:KMDA) posted its quarterly earnings data on Wednesday, August, 16th. The biotechnology company reported $0.04 EPS for the quarter, beating analysts' consensus estimates of $0.02 by $0.02. The biotechnology company had revenue of $37.44 million for the quarter, compared to analysts' expectations of $34.18 million. Kamada had a net margin of 4.07% and a trailing twelve-month return on equity of 5.93%. During the same quarter last year, the business earned $0.07 EPS. What guidance has Kamada issued on next quarter's earnings? Kamada updated its FY 2023 earnings guidance on Monday, November, 13th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $138.00 million-$146.00 million, compared to the consensus revenue estimate of $143.83 million. What other stocks do shareholders of Kamada own? Based on aggregate information from My MarketBeat watchlists, some companies that other Kamada investors own include CA (CA), BlackRock (BLK), Endologix (ELGX), Chipotle Mexican Grill (CMG), Athabasca Oil (ATH), Allergan (AGN), NIC (EGOV), Micron Technology (MU), Teva Pharmaceutical Industries (TEVA) and Aegean Marine Petroleum Network (ANW). Who are Kamada's major shareholders? Kamada's stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Acadian Asset Management LLC (1.17%), Altshuler Shaham Ltd (0.59%), Meitav Investment House Ltd. (0.17%), Y.D. More Investments Ltd (0.03%) and Concourse Financial Group Securities Inc. (0.00%). How do I buy shares of Kamada? Shares of KMDA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. This page (NASDAQ:KMDA) was last updated on 11/28/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Kamada Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.